Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) announced that its Phase III clinical trial evaluating jaktinib in adult patients with moderate-to-severe atopic dermatitis (AD) has met the primary efficacy endpoint. The dual-acting agent, which inhibits both Janus kinase (JAK) and activin receptor type 1 (ACVR1), was first approved in **May 202atomics for *myelofibrosis*.
Clinical Milestone
| Parameter | Details |
|---|---|
| Drug | Jaktinib – novel dual inhibitor |
| Mechanism | JAK inhibition + ACVR1 suppression |
| Indication | Moderate-to-separate atopic dermatitis (AD) |
| Development Stage | Phase III primary endpoint achieved |
| Previous Approval | May 2025: myelofusion subtypes in China |
| Unique Mechanism | ACVR1 inhibition improves iron metabolism & anemia |
Drug Profile & Differentiation
- Dual-Targeting: Simultaneous inhibition of JAK signaling pathway and ACVR1 activity
- Anemia Benefit: ACVR1 suppression specifically addresses iron metabolism imbalances and anemia commonly seen in chronic inflammatory conditions
–Regulatory Foundation: Already approved in China for intermediate/high-risk primary myelofusion (PMF), polycythemia vera-associated MF (PPV-MF), and essential thrombocythemia-associated MF (PET-Matric fusion)
–Safety Advantage: Potential for improved safety profile through selective targeting compared to pan-JAK inhibitors
Commercial Implications
Atopic Dermatitis Market Opportunity
- Global AD Market: Projected $12 billion by 2030 with premium pricing for oral agents
–China AD Patient Population: Estimated 15 million adults with moderate-to-severe disease
–Competitive Landscape: Positioned against existing JAK inhibitors with potential differentiation through ACVR1 mechanism
–Pricing Power: Dual indication strategy enables value-based pricing across multiple therapeutic areas
Strategic Advantages
- Manufacturing Leverage: Existing commercial supply chain from myelofusion approval
–Regulatory Pathway: Streamlined regulatory process based on established safety database
–Market Access: Early entry into China’s growing AD treatment market
–Pipeline Validation: Success validates Zelgen’s dual-targeting approach for other pipeline candidates
Development Roadmap
- Immediate Next Steps: Complete full data analysis and prepare regulatory submissions
–Timeline Expectations: Potential NDA submission Q3 2026 with accelerated review possible given unmet need
–Global Strategy: Consider international partnerships following Chinese approval
–Additional Indications: Evaluate jaktinib in other inflammatory conditions with anemia comorbidity
Financial Impact
The successful Phase III readout represents a significant de-risking event for Zelgen’s pipeline. With myelofusion sales already generating revenue, the AD indication could meaningfully expand total addressable market and support premium valuation.
Forward-Looking Statements
This brief contains forward-looking statements regarding development timelines, regulatory pathways, and commercial expectations for jaktinib. Actual results may differ due to risks inherent in pharmaceutical development including regulatory decisions, competitive dynamics, and market acceptance.-Fineline Info & Tech
